Page 208 - 2022_03-Haematologica-web

Letters to the Editor
especially if a ‘watch and wait’ policy is considered and doi:10.3324/haematol.2021.279507
clinically feasible. Despite our extensive research, we were only able to include a limited number of patients; this underlines the rarity of the disease and makes general con- clusions challenging. To identify these individual cases, an extensive and ongoing (international) collaboration of pedi- atric oncologists, cytogeneticists, immunologists, molecular biologists and clinical geneticists is mandatory for clinical decision-making and the development of diagnostics tools and treatment. Genomic sequencing can identify novel aberrations that could be recurrent. We here present a con- sensus for the preferred diagnostic logistics, based on a broad international consortium with clinicians and investi- gators from the I-BFM AML SG and EWOG MDS. This consensus may support decision-making in these rare infants presenting with myeloproliferative disease.
Eline J.M. Bertrums,1,2,3 C. Michel Zwaan,1,2 Daisuke Hasegawa,4 Valerie de Haas,1,5 Dirk N. Reinhardt,6 Franco Locatelli,7 Barbara de Moerloose,8 Michael Dworzak,9 Arjan Buijs,10 Petr Smisek,11 Alexandra Kolenova,12 Cornelis Jan Pronk,13 Jan-Henning Klusmann,14 Ana Carboné,15 Alina Ferster,16 Evangelia Antoniou,6 Soheil Meshinchi,17 Susana C. Raimondi,18 Charlotte M. Niemeyer,19 Henrik Hasle,20 Marry M. van den Heuvel-Eibrink1,21 and Bianca F. Goemans1,5
1Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands; 2Department of Pediatric Oncology, Erasmus MC, Rotterdam, the Netherlands; 3Oncode Institute, Utrecht, the Netherlands; 4Department of Pediatrics, St. Luke’s International Hospital, Tokyo, Japan; 5Dutch Childhood Oncology Group (DCOG), Utrecht, the Netherlands; 6Department of Pediatric Oncology, University of Duisburg-Essen, Essen, Germany; 7Sapienza, University of Rome Department of Pediatric Hematology-Oncology, IRCCS Bambino Gesù Children’s Hospital, Rome, Italy; 8Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium; 9Children's Cancer Research Institute and St. Anna Kinderspital, Department of Pediatrics, Medical University of Vienna, Vienna, Austria; 10Department of Genetics, University Medical Center, Utrecht, the Netherlands; 11Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic; 12Department of Pediatric Hematology and Oncology, Comenius University Children's Hospital, Bratislava, Slovakia; 13Childhood Cancer Center, Skåne University Hospital, Lund, Sweden; 14Pediatric Hematology, Oncology and Hemostaseology, Hospital for Children and Adolescents, University Hospital of Frankfurt/Main, Goethe-University Frankfurt/Main, Frankfurt, Germany; 15Department of Pediatric Onco-Hematology, University Hospital Miguel Servet, Zaragoza, Spain; 16Department of Hemato-Oncology, Immunology and Transplantation, University Pediatric Hospital Reine Fabiola (ULB), Brussels, Belgium; 17Fred Hutchinson Cancer Research Center, Clinical Research Division, Seattle, WA, USA; 18Department of Pathology, St. Jude Children’s Hospital, Memphis, TN, United States; 19Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany; 20Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark and 21University of Utrecht, Utrecht, the Netherlands.
^Members of I-BFM AML SG and EWOG-MDS are stated in the appendix.
Correspondence:
ELINE J.M. BERTRUMS - e.j.m.bertrums@prinsesmaximacen- trum.nl
Received: June 24, 2021.
Accepted: November 25, 2021. Pre-published: December 2, 2021. Disclosures: no conflicts of interest to disclose.
Contributions: EJMB, BFG and MMHE designed the study and wrote the manuscript; EJMB performed literature review and included the data. BFG and MMHE supervised the study. AK, DJMH, CJP, MD, AC, EA and DNR included patients. AB and SCR reviewed the cytogenetic analyses. MMHE, CJP, DNR, BM, HH, SM, EJMB, CMN, JHK and DH participated in consensus meetings. All authors reviewed the manuscript and provided feedback.
^Appendix: International Berlin-Frankfurt-Münster AML Study Group (I-BFM AML SG) members are: C.M. Zwaan, D. Hasegawa, D.N. Reinhardt, F. Locatelli, B. de Moerloose, M., Dworzak, P. Smisek, A. Kolenova, C.J. Pronk, J.H. Klusmann, A. Carboné, E. Antoniou, H. Hasle, M.M. van den Heuvel-Eibrink and B.F. Goemans. European Working Group of MDS in childhood (EWOG-MDS) members are: F. Locatelli, B. de Moerloose, M. Dworzak, C.M. Niemeyer, H. Hasle and M.M. van den Heuvel- Eibrink
References
1. Roberts I, Izraeli S. Haematopoietic development and leukaemia in Down syndrome. Br J Haematol. 2014;167(5):587-599.
2. Roberts I, Fordham NJ, Rao A, Bain BJ. Neonatal leukaemia. Br J Haematol. 2018;182(2):170-184.
3. Niemeyer CM, Flotho C. Juvenile myelomonocytic leukemia: who's the driver at the wheel? Blood. 2019;133(10):1060-1070.
4. van der Linden MH, Creemers S, Pieters R. Diagnosis and manage- ment of neonatal leukaemia. Semin Fetal Neonatal Med. 2012;17(4):192-195.
5. Bain BJ, Bene MC. Morphological and immunophenotypic clues to the WHO categories of acute myeloid leukaemia. Acta Haematol. 2019;141(4):232-244.
6. Bresters D, Reus AC, Veerman AJ, et al. Congenital leukaemia: the Dutch experience and review of the literature. Br J Haematol. 2002;117(3):513-524.
7. Boztug H, Schumich A, Pötschger U, et al. Blast cell deficiency of CD11a as a marker of acute megakaryoblastic leukemia and tran- sient myeloproliferative disease in children with and without Down syndrome. Cytometry B Clin Cytom. 2013;84(6):370-378.
8. Tunstall O, Bhatnagar N, James B, et al. Guidelines for the investiga- tion and management of transient leukaemia of Down syndrome. Br J Haematol. 2018;182(2):200-211.
9. Flasinski M, Scheibke K, Zimmermann M, et al. Low-dose cytara- bine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study. Blood Adv. 2018;2(13):1532-1540.
10. Coenen EA, Zwaan CM, Reinhardt D, et al. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological enti- ty: a collaborative study by the International-Berlin-Frankfurt- Munster AML-study group. Blood. 2013;122(15):2704-2713.
11. van Dongen JC, Dalinghaus M, Kroon AA, de Vries AC, van den Heuvel-Eibrink MM. Successful treatment of congenital acute myeloid leukemia (AML-M6) in a premature infant. J Pediatr Hematol Oncol. 2009;31(11):853-854.
12.Dastugue N, Duchayne E, Kuhlein E, et al. Acute basophilic leukaemia and translocation t(X;6)(p11;q23). Br J Haematol. 1997;98(1):170-176.
Gruber TA, Downing JR. The biology of pediatric acute megakary- oblastic leukemia. Blood. 2015;126(8):943-949.
13. 14.
15.
de Rooij JD, Branstetter C, Ma J, et al. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genom- ic subsets with varying outcomes. Nat Genet. 2017;49(3):451-456. Noort S, Zimmermann M, Reinhardt D, et al. Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retro- spective study by the I-BFM Study Group. Blood. 2018;132(15):1584- 1592.
764
haematologica | 2022; 107(3)